ORIGINAL RESEARCH article
Front. Neurol.
Sec. Stroke
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1651307
Low-Dose vs Standard-Dose Alteplase for Acute Ischemic Stroke: A Real-World Single-Center Retrospective Study
Provisionally accepted
XinLei Mao1,2*
Si-Si He1Ya-Xi Zhang1Cai-Dan Lin1
Xinxin Chen1Shi-Zheng Zhang1Li-Na Ge1Qing-Qing Zhuang1- 1Department of Neurology, Wenzhou Central Hospital, Wenzhou, China
- 2Wenzhou Central Hospital, Wenzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: To investigate the real-world usage patterns and clinical outcomes of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase in patients with acute ischemic stroke (AIS). Methods: This single-center retrospective study included 707 patients with AIS who received intravenous thrombolysis at Wenzhou Central Hospital from December 2016 to April 2023. Baseline characteristics, treatment selection, and clinical outcomes were analyzed. The primary outcomes were 90-day functional outcomes (mRS 0-1 and mRS 0-2) and the incidence of symptomatic intracranial hemorrhage (sICH). Results: Low-dose alteplase was more commonly used in older patients (P < 0.001) and in those on pre-stroke antithrombotic medications (P < 0.01). Junior physicians were more inclined to use low-dose alteplase compared to senior physicians (P < 0.001). The coefficient of variation in rt-PA dosage selection among different physicians was as high as 61%. There were no significant differences in 90-day functional outcomes (mRS 0-1: OR 0.87, 95% CI 0.62-1.23, P = 0.43; mRS 0-2: OR 1.09, 95% CI 0.78-1.52, P = 0.63) or the incidence of sICH (by NINDS criteria: OR 1.68, 95% CI 0.78-3.62, P = 0.19) between the low-dose and standard-dose groups. Conclusions: The study highlights the complexity of treatment decision-making for intravenous alteplase in AIS, with significant influences from both patient and physician factors. Low-dose alteplase demonstrated similar clinical outcomes to standard-dose alteplase in this real-world setting. Future research should focus on optimizing treatment decisions and improving guideline adherence to enhance patient outcomes.
Keywords: Acute ischemic stroke, alteplase, Low-dose, Standard-dose, Real-world study
Received: 22 Jun 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Mao, He, Zhang, Lin, Chen, Zhang, Ge and Zhuang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: XinLei Mao, 57078692@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.